Lesson 9 — What Comes Next?

Understanding the Complex: What Is Synthetic Biology?

---

In 2010, Craig Venter announced that his team had built the first synthetic bacterial cell.

They had taken the genome of one bacterium (Mycoplasma mycoides), synthesized it chemically — letter by letter — and transplanted it into the empty shell of another bacterium (Mycoplasma capricolum). The resulting cell booted up and began reproducing. It was controlled by a wholly synthetic genome. Its descendants were controlled by copies of that synthetic genome. It was, in Venter's phrase, "the first self-replicating species on the planet whose parent is a computer."

The announcement attracted enormous attention — and some pushback from scientists who noted that the synthetic genome was a copy of an existing genome, not a de novo design. But the technical milestone was real: it demonstrated that a functioning genome of more than a million base pairs could be chemically synthesized and used to direct cellular life.

A decade later, synthetic genomics has moved further. Research groups have synthesized chromosomes, built organisms with expanded genetic codes (using non-natural amino acids), and begun constructing organisms from scratch to serve as research tools and production platforms. The synthesis of human chromosomes remains beyond current capability, but the underlying techniques are advancing steadily.

---

Near term: the next five years.

The applications likely to advance most quickly are those where the biology is already partially worked out and the remaining challenges are engineering and scale.

Cellular agriculture — growing meat, dairy, and fish proteins from cell cultures rather than animals — has made significant progress. Companies like Upside Foods (chicken) and BlueNalu (seafood) have produced edible products; the FDA and USDA cleared cultivated chicken in the US in 2023. The challenge is cost: current production costs are still significantly above conventionally produced meat. Reducing those costs to market-competitive levels is the near-term bottleneck.

mRNA vaccine platforms, accelerated by COVID-19 development, are now being applied to diseases where vaccines have never existed: HIV, malaria, tuberculosis. Phase 3 trials for mRNA malaria vaccines are underway. The same platforms are being used for personalized cancer vaccines — customized to the specific mutations in an individual patient's tumor. Phase 2 results for a Moderna/Merck melanoma vaccine showed meaningful reduction in recurrence rates; Phase 3 trials are ongoing.

Biofoundries — automated, high-throughput biological engineering facilities — are being built at national scale in the UK, US, Singapore, and elsewhere. The goal is to dramatically reduce the cost and time of the design-build-test-learn cycle, enabling the field to move at a speed comparable to software development.

---

Medium term: the next ten to twenty years.

Xenobiology — the engineering of organisms with non-natural biochemistry — is one of the most speculative but potentially transformative directions. If biological organisms can be built using non-natural amino acids or non-natural base pairs (forms of DNA that don't appear in nature), they would be biochemically isolated from natural life — unable to exchange genetic material with natural organisms. This would address some of the ecological containment concerns discussed in Lesson 8.

Synthetic genomes designed from the ground up — not copies of existing genomes, but novel designs optimized for specific purposes — remain a grand challenge. The Genome Project-Write (GP-Write) consortium has proposed synthesizing human chromosomes as a research tool, raising both technical and ethical questions about what such a project should be used for.

Biosensors and "living medicines" — organisms engineered to detect disease signals in the body and release therapeutic compounds in response — are being developed for inflammatory bowel disease, cancer, and metabolic disorders. The technical hurdles are significant (keeping engineered bacteria alive in the gut, ensuring they respond only to the intended signals, preventing immune rejection), but early results in model systems are encouraging.

---

What regulates the pace.

Unlike some technologies — software, for instance — synthetic biology is governed by biological reality as much as by human choices. Evolution imposes constraints on what engineered organisms can do. Cells impose metabolic limits on how much of a desired compound can be produced. Ecosystems are complex and partially unpredictable in how they respond to new biological inputs.

These aren't reasons for pessimism — they're reasons for precision. The field will advance where the biology cooperates, and more slowly where it doesn't.

---

Next lesson: What If...? — three speculative thought experiments about futures this technology could enable.

---

Reading time: approx. 9–10 minutes